Bristol Myers Gets Positive CHMP Opinion for Earlier Abecma Use
By Colin Kellaher
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of earlier use of the Abecma gene therapy it is developing with 2seventy bio.
The New York biopharmaceutical company said the recommendation covers use of Abecma earlier in the treatment course for people with the blood cancer multiple myeloma.
The European Commission, which generally follows CHMP's advice, will now review the recommendation.
Bristol Myers said a green light would make Abecma the first chimeric antigen receptor T-cell, or CAR-T, cell therapy available in the European Union for patients with triple-class exposed relapsed and refractory multiple myeloma earlier in their treatment.
Bristol Myers and 2seventy, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S., with Bristol responsible for manufacturing and commercialization outside of the U.S.
The companies in November said the U.S. Food and Drug Administration is planning to hold an advisory committee meeting on a similar earlier approval for Abecma, pushing the agency's review beyond its Dec. 16 target action date.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 26, 2024 07:44 ET (12:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks